Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin's disease

National Medical Journal of India

Volumn 16, Issue 4, 2003, Pages 199-203

  Raina, Vinod ^a   Sharma, Atul ^a   Mohanti, Bidhu K ^a   Kumar, Rajive ^a   Dawar, Ramesh ^a   Rath, Goura K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; AVASCULAR NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG FATALITY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; INFERTILITY; INTERMETHOD COMPARISON; INTESTINE OBSTRUCTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NAUSEA AND VOMITING; NEUTROPENIA; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; ETOPOSIDE; HODGKIN DISEASE; HUMANS; PREDNISONE; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 0142248332     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. DeVita VT, Serpick AA, Carpone PP. Combination chemotherapy in the treatment of Hodgkin's disease. Ann Intern Med 1970;73:881-95.
2. Bonadona G, Zucali R, Monfardini S, DeLena M, Ushlenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975;36:252-9.
3. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84.
4. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: A report of 8-year results. Ann Intern Med 1986;104:739-46.
5. Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the intergroup trial. J Clin Oncol 1998;16:19-26.
6. Schmoll H. Review of etoposide single-agent activity. Cancer Treat Rev 1982;9: 21-30.
7. Taylor RE, McElwain TJ, Barrett A, Peckham MJ. Etoposide as a single agent in relapsed advanced lymphomas: A phase II study. Cancer Chemother Pharmacol 1982;7:175-7.
8. Canellos GP, Petroni GR, Barcos M, Duggan DB, Peterson BA. Etoposide, vinblastine and doxorubicin: An active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B. J Clin Oncol 1995;13:2005-11.
9. Canellos GP, Anderson JR, Peterson BA, Gottlieb AJ. EVA: Etoposide, vinblastine, doxorubicin (adriamycin): An effective regimen for the treatment of Hodgkin's disease in relapse following MOPP: A study of the Cancer and Leukemia Group B (abstract). Proc Am Soc Clin Oncol 1991;10:273.
10. Chandi L, Kumar L, Kochupillai V, Dawar R, Singh R. Hodgkin's disease: A retrospective analysis of 15 years' experience at a large referral centre. Natl Med J India 1998;11:212-17.
11. Dinshaw KA, Advani SH, Gopal R, Nair CN, TalvalkarGV, Gangadharan P, et al. Management of Hodgkin's disease in western India. Cancer 1984;54:1276-82.
12. Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, MacLennan KA, Haybittle JL, et al. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: Results of a British National Lymphoma Investigation Trial. J Clin Oncol 1992;10:1252-8.
13. Brizel DM, Gockerman JP, Crawford J, Hathorn JW, Moore JO, Osborne B, et al. A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease. Cancer 1994;74:159-63.
14. Schellong G, Potter R, Bramswig J, Wagner W, Prott FJ, Dorfell W, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90. J Clin Oncol 1999;17:3736-44.
15. Pedersen-Bjergaard J, Osterlind K, Hansen M, Philip P, Pedersen AG, Hansen HH. Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung. Blood 1985;66:1393-7.
16. Bajorin DF, Motzer RJ, Rodriguez E, Murphy B, Bosl GJ. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 1993;85:60-2.